IN2014MU00303A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU00303A IN2014MU00303A IN303MU2014A IN2014MU00303A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A IN 303MU2014 A IN303MU2014 A IN 303MU2014A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical composition
- relates
- abiraterone
- abstract
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2015/050175 WO2015114314A1 (en) | 2014-01-28 | 2015-01-27 | Pharmaceutical composition comprising abiraterone |
IN303MU2014 IN2014MU00303A (es) | 2014-01-28 | 2015-01-27 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN303MU2014 IN2014MU00303A (es) | 2014-01-28 | 2015-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MU00303A true IN2014MU00303A (es) | 2015-09-11 |
Family
ID=52462940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN303MU2014 IN2014MU00303A (es) | 2014-01-28 | 2015-01-27 |
Country Status (2)
Country | Link |
---|---|
IN (1) | IN2014MU00303A (es) |
WO (1) | WO2015114314A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
CA3036011A1 (en) * | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
WO2019206472A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
SG11202107948PA (en) * | 2018-12-20 | 2021-08-30 | Pharmaceutical Oriented Services Ltd | Dosage form containing abiraterone acetate |
EP3999040A4 (en) * | 2019-07-15 | 2023-07-19 | Shilpa Medicare Limited | ABIRATERONE ACETATE DISPERSIBLE TABLETS |
AU2020370150A1 (en) * | 2019-10-22 | 2022-05-12 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
CN113384532B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种cyp17抑制剂固体分散体及其制备方法 |
EP3944860A1 (en) * | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
CN115475172B (zh) * | 2021-06-15 | 2023-12-01 | 北京泰德制药股份有限公司 | 一种含有阿比特龙或其药用盐的药用组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013538845A (ja) * | 2010-10-01 | 2013-10-17 | シプラ・リミテッド | デフェラシロクスを含む医薬組成物 |
GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
SG10201709400VA (en) * | 2013-03-15 | 2018-01-30 | Iceutica Inc | Abiraterone acetate formulation |
-
2015
- 2015-01-27 WO PCT/GB2015/050175 patent/WO2015114314A1/en active Application Filing
- 2015-01-27 IN IN303MU2014 patent/IN2014MU00303A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015114314A1 (en) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE054316T2 (hu) | Gyógyászati készítmény rák kezelésére | |
IN2014MU00303A (es) | ||
TW201613901A (en) | New compounds | |
MX2018014154A (es) | Polinucleotidos moduladores. | |
MX2017006217A (es) | Polinucleotidos moduladores. | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
GB2541571A (en) | Pharmaceutical compositions | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
GB201500374D0 (en) | Combined preparations for the treatment of cancer | |
PH12017500239A1 (en) | Abiraterone acetate formulation and methods of use | |
MX2017002489A (es) | Agentes terapeuticos humanos. | |
PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
MX2018003563A (es) | Nuevos compuestos. | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
ZA201703467B (en) | Methods of treating ocular conditions | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
IN2014MU00495A (es) | ||
GB201719584D0 (en) | Pharmaceutical compositions for the treatment of cancer |